MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)

被引：0
|
作者：
Burchardt, A. [1 ]
Andorsky, D. J. [2 ]
Schmidt, B. [3 ]
La Rosee, P. [4 ]
Graeven, U. [5 ]
Czuczman, M. [6 ]
Llorente, M. [6 ]
Li, J. [6 ]
Sharman, J. [7 ]
机构：
[1] Justus Liebig Univ Giessen, Giessen, Germany
[2] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA
[3] Hamatoonkol Uberortliche Gemeinschaftspraxis Pasi, Munich, Germany
[4] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany
[5] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol & Gastroenterol, Monchengladbach, Germany
[6] Celgene Corp, Summit, NJ USA
[7] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V608
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [1] Magnify: A Phase IIIB Trial Shows Promising Efficacy in the Treatment of Relapsed/Refractory, Indolent Non-Hodgkin Lymphoma Patients with Lenalidomide in Combination with Rituximab (R2)
    Rummer, Mathias
    Andorsky, David J.
    Schmidt, Burkhard
    La Rosee, Paul
    Graeven, Illtrich
    Czuczman, Myron
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 238 - 238
  • [2] MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn
    Lansigan, Frederick
    Reynolds, Chris
    Foon, Kenneth A.
    Li, Jiahui
    Llorente, Mary
    Rummel, Mathias J.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2018, 132
  • [4] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [5] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [6] Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Lansigan, Frederick
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Reynolds, Chris
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Jung Ryun
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 104 - 105
  • [7] MAGNIFY Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis
    Lansigan, Frederick
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Reynolds, Chris
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Jung Ryun
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S384 - S384
  • [8] AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.
    Leonard, John
    Gribben, John G.
    Trnen, Marek
    Scheinberg, Phillip
    Tobinai, Kensei
    Fowler, Nathan Hale
    Kilavuz, Nurgul
    Fustier, Pierre
    Amoroso, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin
    Frederick, Lansigan
    David, J. Andorsky
    Morton, Coleman
    Yacoub, Abdulraheem
    Jason, M. Melear
    Suzanne, R. Fanning
    Kathryn, S. Kolibaba
    Chris, Reynolds
    Grzegorz, S. Nowakowski
    Mecide, Gharibo
    Jung, R. Ahn
    Ju, Li
    Mathias, D. Rummel
    Jeff, P. Sharman
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S9 - S10
  • [10] Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma
    Koji Izutsu
    Yosuke Minami
    Noriko Fukuhara
    Yasuhito Terui
    Tatsuro Jo
    Go Yamamoto
    Takayuki Ishikawa
    Tsutomu Kobayashi
    Toru Kiguchi
    Hirokazu Nagai
    Tomoko Ohtsu
    Stacey Kalambakas
    Pierre Fustier
    Shuichi Midorikawa
    Kensei Tobinai
    International Journal of Hematology, 2020, 111 : 409 - 416
12345